晚期子宮漿液性內膜癌的檢視

Advanced stage uterine serous carcinoma

子宮漿液性內膜癌乃一甚為惡性的第II型子宮內膜癌，有較多的局部和遠處轉移，建議治療方式有分期手術、放射線治療和化學治療等。最近，分子醫學的檢查和新藥物的使用，被證實對這類患者的治療效果佳，可增加存活時間比率。在有HER2顯示的患者，加入trastuzumab藥物對治療會有益處，因此建議晚期患者儘早檢查HER2；更且，晚期和復發性患者如使用pembrolizumab和lenvatinib治療，有效反應也可達50%。

Uterine serous carcinoma (USC) is a biologically aggressive type II endometrial cancer, and USC patients are at risk for both regional and distant metastasis, therapeutic guidelines recommend multimodality treatment including complete staging operation, radiotherapy, and chemotherapy. Recent advances in molecular evaluation and treatment of this disease have demonstrated significant benefits in survival outcomes. For HER2 expression in uterine serous carcinoma, the addition of trastuzumab to the therapeutic regimen for patients should be considered, therefore suggesting early testing for HER2 for advanced disease. Furthermore, the administration of pembrolizumab and lenvatinib is considered an essential treatment modality for second-line treatment of advanced stage and recurrence of USC patients, with an objective response rate of 50%.